Related by context. All words. (Click for frequent words.) 71 IU mL 70 detectable HCV RNA 70 mg/m2/day 70 pmol L 69 biochemical relapse 69 microg 69 mg TID 69 PSA nadir 69 μg ml 69 log# reduction 68 pg mL 68 mg m² 68 undetectable HCV RNA 68 serum HBV DNA 68 HIV RNA 68 HBeAg seroconversion 68 ug kg 68 MBq 68 HBV DNA levels 68 plasma HCV RNA 68 cEVR 67 log# copies mL 67 ertapenem 67 serum HCV RNA 67 aspartate aminotransferase 67 microliter 67 HBsAg 67 μmol L 67 PegIFN RBV 67 mcL 66 μg L 66 % Confidence Interval 66 μg mL 66 mCi 66 copies ml 66 ml min 66 mU liter 66 Peg IFN 66 sUA 66 PEG IFN 65 mcg mL 65 ng dL 65 REYATAZ r arm 65 mL/min/#.# m2 65 cells μL 65 antibody titer 65 mIU mL 65 mEq L 65 neutrophil count 65 mL/min/#.# m 2 65 -#.# log# 65 mg kg dose 65 % CI #.#-#.# [003] 65 lymphocytosis 65 mIU ml 65 anti HBs 65 copies mL 65 HBV DNA 65 undetectable hepatitis C 65 microgram kg 64 achieved ACR# 64 cGy 64 CDAI score 64 #.#mg/dL 64 lopinavir r arm 64 undetectable HBV DNA 64 mcg kg 64 #mg/m# [002] 64 alanine aminotransferase ALT 64 severe neutropenia 64 naïve HCV 64 #.#ng/ml 64 certolizumab 64 lactate dehydrogenase 64 cells mcL 64 IFN α 64 evaluable subjects 64 serum urate 64 mmol l 64 pT3 64 mm3 64 log# 63 serum prostate 63 μg kg 63 -#.# log# copies mL 63 #μg [001] 63 complete cytogenetic response 63 mu g 63 pg ml 63 uM 63 aspartate aminotransferase AST 63 mg/m2 dose 63 #ng/ml 63 response CCyR 63 specific antigen PSA 63 undetectable virus HCV 63 ug mL 63 ug ml 63 hours postdose 63 rizatriptan 63 CIN2 + 63 serum aminotransferase levels 63 mcg BID 63 #ug [002] 63 cells uL 63 alanine aminotransferase 63 piperacillin tazobactam 63 mg QD 63 x ULN 63 #.#mg/kg [002] 63 mg qd 63 HCV replicon 63 4mg/kg 63 VELCADE melphalan 63 underwent surgical resection 63 #mg dose [002] 63 tPSA 63 #.#-#.# [011] 63 CCyR 63 PegIFN 63 Median PFS 63 mL sec 63 DAS# CRP 63 uL 63 baseline neutrophil counts 63 concentration Cmax 63 urine albumin 63 neutrophil counts 63 leukocyte count 63 salmeterol fluticasone propionate 63 HCV Genotype 63 CR CRu 63 eosinophil count 63 nM 63 ribavirin RBV 62 tipranavir r 62 Solid Tumors criteria 62 undetectable viral 62 ALT elevation 62 % CI #.#-#.# [007] 62 chlorambucil 62 mmol kg 62 atazanavir ritonavir 62 RNA copies mL 62 baseline FEV 62 μg dose 62 8mg/kg 62 ribavirin therapy 62 progression TTP 62 HBeAg 62 dose cohort 62 mL kg 62 #mg QD [002] 62 SVR# 62 cTnI 62 â ‰ ¥ 62 Partial Response 62 HCV genotype 62 mcg albinterferon alfa 2b 62 relapsed MM 62 nmol liter 62 pmol liter 62 pegylated interferon alpha 62 CR nPR 62 hemagglutination inhibition 62 ìg 62 pmol 62 FOLFOX6 62 rapid virological response 62 undetectable viral load 62 pCR 62 highly emetogenic 62 cm ^ sup 62 #mg/kg [001] 62 μL 62 intramuscularly 62 aminotransferase elevations greater 62 micromolar 62 hemoglobin Hb 62 rFSH 62 MIC# [001] 62 ng ml 62 abacavir lamivudine 62 thyroglobulin 61 mg kg hr 61 μg d 61 μSv 61 nanomolar 61 mg eq 61 HBeAg negative patients 61 transdermal estradiol 61 AUC0 61 moderately emetogenic 61 lactate dehydrogenase LDH 61 intratumoral 61 ACR# response 61 kGy 61 achieved sustained virologic 61 pCi l 61 CIMZIA TM 61 log# IU mL 61 μg dL 61 refractory NSCLC 61 baseline LDH 61 interquartile range 61 injected subcutaneously 61 HBeAg positive patients 61 CRp 61 lopinavir r 61 3mg/kg 61 PASI scores 61 antithymocyte globulin 61 Crohn Disease Activity 61 #μg [002] 61 p# antigen 61 saline placebo 61 preoperative PSA 61 chronic HCV genotype 61 oral allopurinol 61 dexamethasone Decadron 61 μg liter 61 DAS# remission 61 corticosteroid dose 61 hA# 61 binary restenosis 61 symptomatic intracranial hemorrhage 61 cd m 61 serum cortisol 61 amoxicillin clavulanate 61 TPV r 61 Gy fractions 61 pfu 61 mU 61 ^ sup #m 61 #mg/kg [002] 61 ara C 61 mmHg systolic 61 Index CDAI 61 creatinine ratio 61 mg/m2 61 Response Evaluation Criteria 61 mg ustekinumab 61 HCV RNA 61 seroconverted 61 CrCl 61 culture supernatants 61 Platelet counts 61 #mg BID [003] 61 ACR Pedi 61 mcg dose 61 Cmax 61 seroprotection 61 mmHg diastolic 61 endoscopic remission 61 Engerix B 60 HGPIN 60 Index CDAI score 60 FASLODEX #mg 60 partial remissions 60 mm Hg diastolic 60 serum testosterone 60 μg doses 60 mol L 60 nmol 60 Peginterferon Alfa 2a 60 Viral load 60 p = NS 60 treatment naive genotype 60 RECIST criteria 60 adjunctive placebo 60 administered subcutaneously 60 titres 60 achieved CCyR 60 CK # plasma concentrations 60 dosing cohorts 60 DLTs 60 ug dose 60 picogram 60 gemcitabine cisplatin 60 #mg BID [001] 60 KRAS mutations occur 60 hemoglobin A1c HbA1c 60 mU L 60 mCi m 2 60 mCi kg 60 elevated transaminases 60 bortezomib refractory 60 glycated hemoglobin levels 60 intact parathyroid hormone 60 kg -1 60 QTcF 60 iPTH 60 NovoLog ® Mix 60 hemagglutination inhibition HAI 60 low dose cytarabine 60 ppm boron 60 Q2W 60 dimeglumine 60 CK MB 60 5-FU/LV 60 Mg Usa 60 pegylated interferon alfa 2a 60 normal ULN 60 lispro 60 mmol L. 60 EDSS score 60 ABC/3TC 60 3mg 60 -#.# mg dL [002] 60 lymphocyte count 60 deoxyglucose 60 viral titer 60 ng dl 60 5 Fluorouracil 60 hypophosphatemia 60 serum phosphorus 60 serum potassium 60 Mg Uk 60 ARB telmisartan 60 annualized relapse 60 plus prednisone prednisolone 60 clodronate 60 seronegative 60 NOAEL 60 HI titers 60 statistical significance p 60 Plasma concentrations 60 PSADT 60 tolterodine ER 60 comparator arm 60 fraction LVEF 60 #mg #mg #mg [003] 60 rapid virologic response 60 prospectively defined 60 OGTT 60 mitoxantrone chemotherapy 60 anagrelide 60 RECIST Response Evaluation Criteria 60 #mg/dl 60 #mg/m# [001] 60 elevated ALT 60 adefovir treated 60 normoxic 60 mm ³ 60 g dl 60 infliximab monotherapy 60 IgG antibody 60 daunorubicin 60 creatinine clearance 60 median PFS 60 Ondansetron Injection USP 60 ≥ 60 HCV genotypes 60 chemoradiation therapy 60 sustained virological response 60 serum phosphorous 60 serum concentrations 60 peginterferon alfa 60 complete cytogenetic 60 HBeAg + 60 generalized edema 60 invasive carcinomas 60 pyrazinamide 60 urate lowering therapy 60 paraprotein 60 EGFR TKI 60 mRCC 60 immunostaining 60 PREZISTA r arm 60 q#h 60 extracapsular extension 59 #mg q8h 59 g mL 59 IRLS score 59 LEXIVA r 59 Serum creatinine 59 nmol L 59 isoprostane 59 micrograms mL 59 antibody titers 59 CD3 + 59 Pharmacokinetic parameters 59 ng mL 59 calculated creatinine clearance 59 mesalamine granules 59 tuberculin skin testing 59 seropositivity 59 bioavailable testosterone 59 moderate renal impairment 59 IIIa inhibitors 59 glutamyl 59 achieved PASI 59 APTIVUS r 59 ritonavir boosted 59 FOLFIRI alone 59 acute GvHD 59 mm Hg systolic 59 Immunohistochemical staining 59 complete Early Virological 59 telaprevir dosed 59 mEq 59 isoenzyme 59 Psoriasis Area 59 inhibitory concentration 59 tumor xenograft models 59 cm2 59 ALT normalization 59 postmenopausal osteoporotic women 59 mg m 59 elevated LDH 59 topical gel formulation 59 subcutaneously injected 59 mg tid 59 Hb A1C 59 cytarabine daunorubicin 59 posttreatment 59 intravenous bolus injection 59 creatine kinase CK 59 liposomal doxorubicin 59 achieved sustained virological 59 mitoxantrone plus 59 infused intravenously 59 mcg QD 59 microliters 59 pegylated alpha interferon 59 SGPT 59 Fasting blood glucose 59 aminotransferases 59 serum phosphate 59 oral prednisone 59 g dL 59 kBq kg 59 intercellular adhesion molecule 59 urinary N telopeptide 59 serum magnesium 59 secondary efficacy endpoint 59 intravenous bolus 59 leukocytosis 59 genotypic resistance 59 alanine transaminase 59 HES CEL 59 simvastatin #mg 59 cells/mm3 59 peripheral blood mononuclear 59 dosing cohort 59 ALT elevations 59 TURBT 59 viral titers 59 plus ribavirin 59 Solid Tumors RECIST 59 busulfan 59 CDAI 59 HBeAg positive 59 #.#mL 59 reduce serum phosphate 59 amprenavir 59 metastatic GIST 59 oblimersen 59 peginterferon alfa 2a 59 tissue transglutaminase 59 CLL SLL 59 postintervention 59 X ULN 59 mg/m2 IV 59 baseline Hb 59 metastatic malignant 59 mL vials 59 anthracycline taxane 59 salmeterol fluticasone 59 lanthanum carbonate 59 histrelin 59 estramustine 59 permanently discontinue Vectibix 59 bFGF 59 #mg/dL [002] 59 postvaccination 59 macrolide antibiotic 59 SUVmax 59 COMBIVIR 59 achieved undetectable HCV 59 plasma uric acid 59 Severity Index PASI 59 aminotransferase levels 59 mitomycin 59 6mg 59 Copegus ribavirin 59 Virologic 59 femtogram 59 flutamide 59 Pemetrexed 59 PaO 2 59 μmol 59 recurrent genital herpes 59 low dose Iluvien 59 evaluable 58 alfa 2a 58 #.#/#.# mm Hg [003] 58 Known hypersensitivity 58 octreotide LAR 58 #mg/day [002] 58 seroconversion 58 K#N 58 mg orally 58 μM 58 Secondary endpoints include 58 g cm 58 colorectal carcinoma 58 p = #.# [003] 58 #OHD 58 microbiological eradication 58 macroalbuminuria 58 ‰ ¥ 58 fosamprenavir 58 supernatants 58 endometrial thickness 58 dosed intravenously 58 interleukin IL -6 58 IV bolus 58 cervical intraepithelial neoplasia 58 ^ sup -1 58 fasting plasma glucose FPG 58 budesonide pMDI 58 intraperitoneally 58 MADRS score 58 kBq 58 cfu 58 receiving highly emetogenic 58 Retreatment 58 oral levofloxacin 58 dopamine partial agonist 58 FluCAM arm 58 morphometric vertebral fractures 58 Hemoglobin A1c HbA1c 58 cubic milliliter 58 #mmHg [001] 58 F FDG PET 58 biochemical recurrence 58 GnRH agonist 58 remission CR 58 HCV RESPOND 2 58 anemia hemoglobin 58 mmol liter 58 treatment naïve genotype 58 Flu Cy 58 Rapid Virological Response 58 receiving prophylactic anticoagulation 58 deep venous thromboses 58 Pharmacokinetics PK 58 reactogenicity 58 Lupuzor ™ 58 TMC# r 58 adriamycin 58 dasatinib Sprycel ® 58 Aptivus ® 58 indinavir 58 Folfox 58 intradermal injections 58 atorvastatin #mg 58 SCIg 58 ug l 58 postdose 58 noninferior 58 Abstract Number 58 seroprotective 58 Pegasys plus Copegus 58 TUNEL 58 fluticasone salmeterol 58 inhibitory concentrations 58 erythrocyte sedimentation rate 58 unfractionated heparin UFH 58 q8h 58 FOLFOX4 58 achieve sustained virologic 58 TAXOTERE R 58 MCyR 58 immune globulin intravenous 58 BARACLUDE ® 58 FLT3 ITD 58 stage IIIb IV 58 virologic failure 58 QRS duration 58 oral diclofenac 58 mg subcutaneously 58 glomerular filtration 58 bronchoalveolar lavage 58 receiving INTRON 58 sub maximal 58 estimated glomerular filtration 58 serum creatinine levels 58 TIMP 58 HCV antibody 58 mg/# hours 58 placebo PBO 58 peginterferon alpha 2a 58 glycosylated hemoglobin HbA1c 58 sUA levels 58 doxorubicin cyclophosphamide 58 protein excretion 58 nmol L. 58 XIENCE V PROMUS Stent 58 BENICAR HCT 58 μS cm 58 Tmax 58 Visual Analogue Scale VAS 58 mcg kg min 58 virologic response 58 Target Lesion Revascularization TLR 58 ritonavir boosted lopinavir 58 timolol 58 mmol 58 % CI #.#-#.# [008] 58 NNT = 58 transaminases 58 tipranavir ritonavir 58 gemcitabine carboplatin 58 ml kg 58 nodular partial response 58 ethambutol 58 micromoles 58 FDG uptake 58 peginterferon alfa 2a #KD 58 Hycamtin ® 58 #mg/day [001] 58 Acetate Rectal Suppositories 58 CD4 CD8 58 leucopenia 58 mg BID 58 plasma concentrations 58 SCr 58 preintervention 58 ALT flares 58 dacarbazine 58 mg XP# 58 serum albumin 58 CI -#.# 58 μg dl 58 NRTI resistance 58 pegIFN 58 ceftazidime 58 glycated hemoglobin 58 Bq 58 #mg ATC 58 IFN alpha 58 daily subcutaneous injections 58 interferon alfa 2b 58 Median survival 58 biologic DMARD 58 IgG antibodies 58 docetaxel Taxotere 58 prior chemotherapy regimens 58 azacytidine 58 docetaxel chemotherapy 58 CIN2 58 #mg/#mg 58 IFN beta 58 pegylated interferon alfa 58 microalbumin test 57 Rate ORR 57 genotype 1b 57 serum antibody 57 goserelin 57 HER2 expression 57 nondiabetic patients 57 S. aureus isolates 57 plus aztreonam 57 AST ALT 57 μmol l 57 CIMZIA ™ 57 DOXIL 57 Interferon alfa 57 tryptase 57 abnormal p# biomarker 57 mg RDEA# 57 MAGE A3 ASCI 57 imiquimod cream 57 serum ferritin 57 SGOT 57 epoetin alpha 57 Median progression 57 viremia 57 plasma cortisol 57 umol L 57 glulisine 57 #mg QD [001] 57 sitosterol 57 histologically confirmed 57 DAS# [002] 57 LANTUS R 57 mIU L 57 fluorouracil leucovorin 57 #mg/dL [001] 57 alefacept 57 tositumomab 57 sustained virologic response 57 tacrolimus ointment 57 mL min 57 Biaxin clarithromycin 57 μg l 57 splenectomized patients 57 apolipoprotein B 57 injected intramuscularly 57 chlorhexidine gluconate 57 Pegasys ® 57 dose dexamethasone 57 serum IGF 57 caspofungin 57 milliliters mL 57 liposome formulation 57 glucuronide 57 mGy 57 1ppm 57 cardiac troponin T 57 x #mm WDH [001] 57 % CI #.#-#.# [006] 57 anti CTLA 57 Qmax 57 microbiologically evaluable 57 mu m 57 parasitemia 57 PREZISTA r 57 intranasally administered 57 euthyroid 57 iodixanol 57 Hb A1c 57 mg kg bw 57 posttransplant 57 interferon alfa 57 mg q8h 57 mL 57 ohm cm 57 median CD4 57 Non inferiority 57 serum thyroglobulin 57 oocytes retrieved 57 HBeAg negative 57 grade cervical intraepithelial 57 metformin monotherapy 57 serum phosphorus levels 57 anastrazole 57 Btk Inhibitor PCI 57 subcutaneous dose 57 EUFLEXXA R 57 cyclophosphamide methotrexate 57 neurologic progression 57 steroid dexamethasone 57 mg d 57 efavirenz EFV 57 K ras mutations 57 TLUS 57 μl 57 Sustained virologic response 57 insulin glulisine 57 picomolar 57 imipenem 57 virologic response EVR 57 plus OBT 57 peg IFN 57 serum ALT 57 cytokeratin 57 receptor tyrosine kinase inhibitor 57 μg 57 CIN3 + 57 Camptosar ® 57 hematologic toxicity 57 plus dexamethasone 57 ELISPOT 57 carmustine 57 Decitabine 57 overt nephropathy 57 tsp vanilla extract 57 aminotransferase ALT 57 ovarian carcinoma 57 mW cm 2 57 ritonavir boosted atazanavir 57 uninfected mice 57 docetaxel Taxotere ® 57 metastatic CRC 57 galiximab 57 Partial Responses 57 NNRTI resistance 57 HbA1C 57 viral kinetics 57 achieved mucosal healing 57 Kaplan Meier 57 free survival PFS 57 #ug [001] 57 replicon 57 HPV-#/# 57 mg q#h 57 CI #.#-#.# [001] 57 crossclamp 57 TIMP 1 57 Bezielle 57 Supplementary Table 57 transaminase 57 FOLFOX4 alone 57 #mL [001] 57 intravenous IV infusion 57 brivanib 57 cefotaxime 57 renal cell carcinomas 57 parasitaemia 57 Left Ventricular Ejection Fraction 57 virological response 57 cefazolin 57 Annexin V 57 hepatoma 57 intradermally 57 IOP lowering 57 undergone splenectomy 57 intravitreal injection 57 p = .# [002] 57 lumbar spine BMD 57 Pegylated Liposomal Doxorubicin 57 fructosamine 57 alteplase 57 normothermic 57 Paraplatin ® 57 nadir CD4 cell 57 systemic absorption 57 maximal dose 57 mcg Albuferon 57 fasting triglyceride levels 57 hemoglobin hematocrit 57 KRAS wild 57 tumor progression TTP 57 blood phenylalanine Phe 57 hematological parameters 57 troponin T 57 lamivudine refractory patients 57 adefovir 57 interleukin IL 57 dehydroepiandrosterone sulfate 57 prednisone prednisolone 57 Rapid Virologic Response 57 mg BID dose 57 g t Beryllium 57 Arch Intern Med 57 oral Hycamtin 57 antiandrogen 57 kilogram mg kg 57 alkylating agent 57 confidence interval CI 57 chloride secretion 57 amikacin 57 Interferon gamma 57 Free Survival PFS 57 microlitres 57 Wistar rats 57 baseline serum creatinine 57 locoregional recurrence 57 Pred Forte 57 null responders 57 creatine phosphokinase 57 q#d 57 pulmonary exacerbations 57 deoxy 57 nicardipine 56 Primary endpoints 56 Alanine 56 CANCIDAS 56 melphalan prednisone 56 micrograms mcg 56 GHRH 56 febrile neutropenia 56 -#.# ± [002] 56 serum TSH 56 N telopeptide 56 methicillin sensitive 56 IGFBP 56 oral FTY# 56 pegylated IFN 56 acute gout flares 56 timepoints 56 Doxil ® 56 F FLT 56 HIV uninfected 56 PASI score 56 creatine kinase MB 56 argc 56 NMIBC 56 pT2 56 mg niacin 56 myocardial necrosis 56 imatinib therapy 56 virologic breakthrough 56 6MW distance 56 liposome injection 56 mg kg ip 56 #mg BID [002] 56 microgram mcg 56 per deciliter mg 56 underwent resection 56 BUPHENYL R sodium phenylbutyrate 56 transaminase levels 56 PSMA ADC 56 iobenguane 56 HbA 1c 56 glomerular filtration rate 56 CIMZIA TM certolizumab pegol 56 ULORIC 56 IgM 56 Parathyroid Hormone 56 Peginterferon 56 advanced adenoma 56 del 5q 56 ug L 56 hemodynamically significant 56 CIN3 56 mso footer margin 56 ° C ± 56 ^ F FDG 56 gastric adenocarcinoma 56 NS#/#A protease 56 recurrent glioblastoma multiforme 56 Kaplan Meier estimate 56 ACR# responses 56 x #mm WDH [002] 56 locoregional 56 prostate carcinoma 56 cytogenetic response 56 Tumor Response 56 Secondary endpoints included 56 virologic suppression 56 mg kg intravenously 56 oral vancomycin 56 isoproterenol 56 1mg 56 PREZISTA rtv 56 P = .# 56 delivered subcutaneously 56 statin monotherapy 56 cisplatin vinorelbine 56 % miconazole nitrate 56 postoperative chemotherapy 56 fluoropyrimidine 56 oxacillin 56 prednisone prednisolone plus 56 pegylated interferon alpha 2a 56 achieved statistical significance 56 microalbumin 56 Negative Syndrome 56 albumin excretion rate 56 Xeloda ® 56 pharmacokinetic PK profile 56 patients evaluable 56 STELARA ® 56 advanced adenomas 56 antiretroviral naive 56 neutropaenia 56 hepatitis C genotype 56 microvessel density 56 myelodysplastic myeloproliferative diseases 56 HBV infections 56 pleural fluid 56 rhEPO 56 QD dosing 56 pg g 56 interferon alfa 2a 56 MΩ 56 oral rivaroxaban 56 pegylated interferon alfa 2b 56 serum sodium concentration 56 titers 56 #.#μm [001] 56 BCG vaccinated 56 experienced virologic failure 56 oral antidiabetic medication 56 Zidovudine Tablets 56 voriconazole 56 CFU ml 56 neutropenia dehydration dyspnea 56 5alpha reductase 56 deciliter 56 HOLE NO 56 oxycodone CR 56 Kaplan Meier estimates 56 mg calcium 56 CsA 56 papillary renal cell carcinoma 56 serum urate levels 56 M#V 56 intravenous REOLYSIN 56 liver histology 56 nmol l 56 low expressors 56 Elitek 56 8mg 56 A1c levels 56 tumors GIST 56 HER2 amplification 56 vitamin B# folic acid 56 intramuscular dose 56 mg kg cohorts 56 serum LDL cholesterol 56 NPH insulin 56 transaminase elevations 56 CHOP chemotherapy 56 bortezomib Velcade R